140 related articles for article (PubMed ID: 34333197)
1. TACE plus PD-1 inhibitor (Camrelizumab) treatment for bridging to tumor resection in HCC: Case reports.
Xin H; Zhang C; Ding Z; Zhang M; Ding G; Li N
Clin Res Hepatol Gastroenterol; 2022 Jan; 46(1):101777. PubMed ID: 34333197
[No Abstract] [Full Text] [Related]
2. Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Camrelizumab Compared With Conventional Transarterial Chemoembolization Plus Camrelizumab for Unresectable Hepatocellular Carcinoma.
Ren Y; Guo Y; Chen L; Sun T; Zhang W; Sun B; Zhu L; Xiong F; Zheng C
Cancer Control; 2022; 29():10732748221076806. PubMed ID: 35343254
[TBL] [Abstract][Full Text] [Related]
3. Real-world treatment patterns and outcomes for patients with advanced hepatocellular carcinoma initially treated with PD-1 inhibitors.
Zou H; Ge Y; Chen W; Yao D; Oi Lam Ung C; Lai Y; Hu H
Int Immunopharmacol; 2024 May; 132():111947. PubMed ID: 38552296
[TBL] [Abstract][Full Text] [Related]
4. Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma.
Guo Y; Ren Y; Chen L; Sun T; Zhang W; Sun B; Zhu L; Xiong F; Zheng C
BMC Cancer; 2022 Mar; 22(1):270. PubMed ID: 35287627
[TBL] [Abstract][Full Text] [Related]
5. Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination.
Ju S; Zhou C; Hu J; Wang Y; Wang C; Liu J; Yang C; Huang S; Li T; Chen Y; Bai Y; Yao W; Xiong B
BMC Cancer; 2022 Mar; 22(1):335. PubMed ID: 35346114
[TBL] [Abstract][Full Text] [Related]
6. Case Report: Successful treatment of advanced hepatocarcinoma with the PD-1 inhibitor Camrelizumab.
Ye W; Cai L; Zhang M; Wu Y; Sun H; Wang YD; Xia Y
Front Immunol; 2023; 14():1221418. PubMed ID: 37575222
[TBL] [Abstract][Full Text] [Related]
7. The clinical application of camrelizumab on advanced hepatocellular carcinoma.
Chen Z; Lu X; Koral K
Expert Rev Gastroenterol Hepatol; 2020 Nov; 14(11):1017-1024. PubMed ID: 32762583
[TBL] [Abstract][Full Text] [Related]
8. Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial.
Wang F; Qin S; Sun X; Ren Z; Meng Z; Chen Z; Chai X; Xiong J; Bai Y; Yang L; Zhu H; Fang W; Lin X; Chen X; Li E; Wang L; Yan P; Zou J
J Hematol Oncol; 2020 May; 13(1):47. PubMed ID: 32393323
[TBL] [Abstract][Full Text] [Related]
9. Camrelizumab: an investigational agent for hepatocellular carcinoma.
Xu B; Sun HC
Expert Opin Investig Drugs; 2022 Apr; 31(4):337-346. PubMed ID: 34937475
[TBL] [Abstract][Full Text] [Related]
10. Hepatic Resection after Initial Transarterial Chemoembolization Versus Transarterial Chemoembolization Alone for the Treatment of Hepatocellular Carcinoma: A Meta-analysis of Observational Studies.
Tang YL; Qi XS; Guo XZ
Asian Pac J Cancer Prev; 2015; 16(17):7871-4. PubMed ID: 26625813
[TBL] [Abstract][Full Text] [Related]
11. Transarterial chemoembolization plus multi-imaging-guided radiofrequency ablation for elimination of hepatocellular carcinoma nodules measuring 3.1 to 5.0 cm: a single-center study.
Haochen W; Jian W; Li S; Tianshi L; Xiaoqiang T; Yinghua Z
J Int Med Res; 2018 Jul; 46(7):2650-2657. PubMed ID: 29683022
[TBL] [Abstract][Full Text] [Related]
12. Current Status and Prospects of Camrelizumab, A Humanized Antibody Against Programmed Cell Death Receptor 1.
Song H; Liu X; Jiang L; Li F; Zhang R; Wang P
Recent Pat Anticancer Drug Discov; 2021; 16(3):312-332. PubMed ID: 33563158
[TBL] [Abstract][Full Text] [Related]
13. [Transarterial chemoembolization (TACE) in hepatocellular carcinoma: technique, indication and results].
Vogl TJ; Zangos S; Balzer JO; Nabil M; Rao P; Eichler K; Bechstein WO; Zeuzem S; Abdelkader A
Rofo; 2007 Nov; 179(11):1113-26. PubMed ID: 17948190
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitor for hepatocellular carcinoma recurrence after liver transplantation.
Zhuang L; Mou HB; Yu LF; Zhu HK; Yang Z; Liao Q; Zheng SS
Hepatobiliary Pancreat Dis Int; 2020 Feb; 19(1):91-93. PubMed ID: 31706859
[No Abstract] [Full Text] [Related]
15. Conversion surgery for advanced hepatocellular carcinoma after combination treatment of lenvatinib and camrelizumab: a case report.
Chen Z; Chen Z; Fan W; Zou Y; Zhang Y; Shi N; Jin H
World J Surg Oncol; 2023 Jan; 21(1):29. PubMed ID: 36721173
[TBL] [Abstract][Full Text] [Related]
16. AGA Technical Review on Systemic Therapies for Hepatocellular Carcinoma.
Altayar O; Shah R; Chang CY; Falck-Ytter Y; Muir AJ
Gastroenterology; 2022 Mar; 162(3):937-951. PubMed ID: 35210015
[No Abstract] [Full Text] [Related]
17. Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial.
Mei K; Qin S; Chen Z; Liu Y; Wang L; Zou J
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741732
[TBL] [Abstract][Full Text] [Related]
18. bMSAF is a prognostic predictor for advanced hepatocellular carcinoma patients treated with immune checkpoint inhibitor camrelizumab and anti-angiogenic agent apatinib combination therapy.
Xu G; Cui L; Li J; Wang Q; Li P; Xia X; Yi X; Guan Q; Xu J
Clin Transl Med; 2022 Oct; 12(10):e1086. PubMed ID: 36245284
[No Abstract] [Full Text] [Related]
19. Case Report: Antiangiogenic Therapy Plus Immune Checkpoint Inhibitors Combined With Intratumoral Cryoablation for Hepatocellular Carcinoma.
Li X; Xu J; Gu X; Chen L; Wu Q; Li H; Bai H; Yang J; Qian J
Front Immunol; 2021; 12():740790. PubMed ID: 34733279
[TBL] [Abstract][Full Text] [Related]
20. Preoperative transarterial chemoembolization and resection for hepatocellular carcinoma: a nationwide Taiwan database analysis of long-term outcome predictors.
Shi HY; Wang SN; Wang SC; Chuang SC; Chen CM; Lee KT
J Surg Oncol; 2014 Apr; 109(5):487-93. PubMed ID: 24293372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
